Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Lund January 9, 2017 - Active Biotech AB (Nasdag Stockholm: ACTI) announces today that the European Patent Office has decided to grant Active Biotech's patent application covering tasquinimod for use in the treatment of multiple myeloma. The patent will be granted as European Patent No. 3041472 on February 1, 2017 and has a duration lasting until 2035.
For further information, please contact:
| Tomas Leanderson, President & CEO Tel: +46 46 19 20 95 Hans Kolam, CFO Tel: +46 46 19 20 44 | Active Biotech AB (Org.nr 556223-9227) Box 724, 220 07 Lund Tel: +46 46 19 20 00 |
About tasquinimod
Tasquinimod is an immunomodulatory, anti-metastatic and anti-angiogenic compound that affects the tumor's ability to grow and spread. The development of tasquinimod has previously been focused on the treatment of prostate cancer with clinical proof of concept and a good safety profile shown in Phase 2 and 3 studies. Tasquinimod's mechanism of action is broadly applicable as anti-tumor treatment and very good results have been achieved in models for multiple myeloma, a blood cancer with a high medical need. Active Biotech is seeking a partner for the continued development of tasquinimod in multiple myeloma.
Active Biotech AB (publ) (Nasdag Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.
This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.00 pm CET on January 9, 2017.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/54311b72-eb9f-4451-ac41-4c9d3b892f19
